Sleeping beauty TCR-T targeting neoantigens (National Cancer Institute)

N/A

Report date: 2022/12/27 09:23:11

Base Information

Drug NameSleeping beauty TCR-T targeting neoantigens (National Cancer Institute)
Drug Alias Nameanti-mutated neoantigen TCR T-cell therapy (National Cancer Institute)Sleeping beauty TCR-T targeting mutated neoantigens (National Cancer Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Gene editing > Sleeping Beauty transposon/transposase system
Mechanisms of ActionT lymphocyte replacementsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A